Skip to main content

Fabry Disease

  • Book
  • © 2010

Overview

  • first full-length textbook about Fabry disease
  • includes chapters on the therapeutic management options
  • complete and stat-of-the-art range of pre-clinical studies
  • comprehensive chapters on clinical findings
  • all authors are experts with many years of clinical and research experience

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (32 chapters)

  1. Pre-Clinical

  2. Clinical

Keywords

About this book

Fabry disease is an X-linked inborn error of metabolism wherein deficiency of a lysosomal enzyme results in systemic deposition of glycosphingolipids. Storage deposition, and hence pathological disease, occurs preferentially in renal glomerular and tubular epithelial cells, myocardial cells, heart valve fibrocytes, neurons of dorsal root ganglia, and in endothelial smooth muscle cells of blood vessels. Thus, Fabry disease is a multi-system disorder, albeit with considerable phenotypic heterogeneity in onset and in severity; however, it is progressive, exhibits extensive morbidity, and is life-threatening. Within the past two decades, there has been a radical change in the natural course Fabry disease by virtue of the availability of specific enzyme replacement therapy. Moreover, there has been a concerted effort to better understand the underlying pathology and equally to identify patients prior to the onset of irreversible end-organ damage. It is to be hoped that the future for patients with Fabry disease can be viewed with greater, albeit guarded, optimism. This state-of-the-art textbook attempts to bridge the span of pre-clinical studies, clinical finding, and management options in a readable but comprehensive manner for the medical practitioner as well as the interested non-medical reader.

Reviews

From the reviews:

“As the first book dedicated to Fabry Disease, this provides an extensive, detailed review of all current information about this rare disorder. … The information presented here will serve genetics specialists in the evaluation, surveillance, and management of affected patients with this rare disorder.  … It is also a well-written and informative tool for families affected by this disorder, helping them understand its natural course and available treatment. … This highly specialized, unique book on this rare disorder has no comparison.” (Luis F. Escobar, Doody’s Review Service, March, 2012)

Editors and Affiliations

  • , Shaare Zedek Medical Center, Gaucher Clinic, Jerusalem, Israel

    Deborah Elstein

  • , Shaare Zedek Medical Center, Genetics Unit, Jerusalem, Israel

    Gheona Altarescu

  • University of Mainz, Children's Hospital, Mainz, Germany

    Michael Beck

Bibliographic Information

  • Book Title: Fabry Disease

  • Editors: Deborah Elstein, Gheona Altarescu, Michael Beck

  • DOI: https://doi.org/10.1007/978-90-481-9033-1

  • Publisher: Springer Dordrecht

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Science+Business Media B.V. 2010

  • Hardcover ISBN: 978-90-481-9032-4Published: 12 August 2010

  • Softcover ISBN: 978-94-007-9884-7Published: 29 September 2014

  • eBook ISBN: 978-90-481-9033-1Published: 02 August 2010

  • Edition Number: 1

  • Number of Pages: XXXVII, 512

  • Topics: Metabolic Diseases, Human Genetics

Publish with us